Futibatinib (Lytgobi) for Cholangiocarcinoma
The Medical Letter on Drugs and Therapeutics · 2023
DOI: 10.58347/tml.2023.1674f ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
The oral kinase inhibitor futibatinib (Lytgobi – Taiho) has received accelerated approval from the FDA for treatment of adults with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusions or other rearrangements. Accelerated approval was based on the overall response rate and duration of response. Futibatinib is the second drug to be approved for this indication; pemigatinib (Pemazyre) was approved earlier.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2023). Futibatinib (Lytgobi) for Cholangiocarcinoma. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1674f
Vancouver
Futibatinib (Lytgobi) for Cholangiocarcinoma. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1674f
BibTeX
@article{euvimed2023,
title = {Futibatinib (Lytgobi) for Cholangiocarcinoma},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2023},
doi = {10.58347/tml.2023.1674f}
}
EUVIMED